

**SHINECO, INC.**  
**Room 1001, Building T5, DaZu Square**  
**Daxing District, Beijing 100176**  
**People's Republic of China**

**Notice of Annual Meeting of Stockholders**

**Date:** June 15, 2021  
**Time:** 9:00 p.m. EST  
**Location:** Room 3106, Building B, Jianwai SOHO,  
Chaoyang District, Beijing 100022  
People's Republic of China  
**Record Date:** April 30, 2021

**Proposals:**

1. Re-elect seven directors to the Board of Directors (the "Board") of Shineco, Inc. (the "Company") to serve until their successors are duly elected and qualified at the 2022 annual meeting of stockholders or until their earlier resignation or removal; and
2. Ratify the appointment of Centurion ZD CPA & Co. ("CZD") as the independent registered public accounting firm of the Company for the fiscal year ending June 30, 2021.

**THE BOARD RECOMMENDS THAT YOU VOTE "FOR" EACH OF THE DIRECTOR NOMINEES INCLUDED IN PROPOSAL NO. 1 AND "FOR" PROPOSAL NO. 2.**

Holders of record of the Company's common stock at the close of business on April 30, 2021 (the "Record Date") will be entitled to notice of, and to vote at, the 2021 annual meeting of stockholders of the Company (the "Meeting") and any adjournment or postponement thereof. Each share of common stock entitles the holder thereof to one vote.

Your vote is important, regardless of the number of shares you own. Even if you plan to attend the Meeting in person, it is strongly recommended that you complete the enclosed proxy card before the meeting date, to ensure that your shares will be represented at the Meeting if you are unable to attend.

A complete list of stockholders of record entitled to vote at the Meeting will be available for 10 days before the Meeting at the principal executive office of the Company for inspection by stockholders during ordinary business hours for any purpose germane to the Meeting.

This notice and the enclosed proxy statement are first being mailed to stockholders on or about May 12, 2021.

You are urged to review carefully the information contained in the enclosed proxy statement prior to deciding how to vote your shares.

**By Order of the Board,**

Date: May 10, 2021

By: /s/ Ou Yang  
Name: Ou Yang  
Title: Chief Executive Officer  
(Principal Executive Officer)

**IF YOU RETURN YOUR PROXY CARD WITHOUT AN INDICATION OF HOW YOU WISH TO VOTE, YOUR SHARES WILL BE VOTED "FOR" ALL OF THE PROPOSALS LISTED ABOVE.**

---

**Important Notice Regarding the Availability of Proxy Materials  
for the 2021 Annual Meeting of Stockholders to be held at 9:00 p.m. EST on June 15, 2021**

The Notice of the Annual Meeting of Stockholders, this proxy statement, and our Annual Report on Form 10-K for the period ended June 30, 2020 (the “Annual Report”) are available at <http://tianyiluobuma.com>.

---

## Table of Contents

	<b>Page</b>
<b>Notice of Annual Meeting of Stockholders</b>	1
<b><u>Questions and Answers about these Proxy Materials</u></b>	4
<b><u>General Information about the Meeting and Voting</u></b>	5
<b><u>Proposal No. 1 — Re-Election of Directors</u></b>	6
<u>Nominee Information</u>	7
<u>Corporate Governance Practices and Policies</u>	7
<u>Board and Committee Independence</u>	7
<u>Board Committees and Meetings</u>	7
<u>Board Role in Risk Oversight</u>	9
<u>Code of Conduct and Ethics</u>	9
<u>Family Relationships</u>	9
<u>Legal Proceedings Involving Officers and Directors</u>	10
<u>Stockholder Communications with the Board</u>	10
<u>Director Compensation</u>	10
<u>Executive Officers</u>	11
<u>Executive Compensation</u>	11
<u>Section 16 (a) Compliance</u>	12
<u>Security Ownership of Certain Beneficial Owners and Management</u>	12
<u>Certain Relationships and Related Party Transactions</u>	13
<b><u>Proposal No. 2 — Ratification of Appointment of Independent Registered Public Accounting Firm</u></b>	14
<u>Change of Independent Registered Public Accounting Firm</u>	15
<u>Fees Paid to the Independent Registered Public Accounting Firm</u>	15
<u>Policies and Procedures Relating to Approval of Services by our Independent Registered Public Accountants</u>	16
<u>Audit Committee Report</u>	16
<b><u>Other Matters</u></b>	17
<b><u>Other Important Information</u></b>	17
<u>Deadline for Submission of Stockholder Proposals for 2022 Annual Meeting of Stockholders</u>	17
<u>Proxy Solicitation</u>	17
<u>Annual Report</u>	17
<u>Delivery of Proxy Materials to Households</u>	17
<u>Where You Can Find Additional Information</u>	18

## Questions and Answers about these Proxy Materials

### Why am I receiving this proxy statement?

In this proxy statement, we refer to Shineco, Inc. as the “Company,” “we,” “us,” or “our.”

This proxy statement describes the proposals on which our Board would like you, as a stockholder, to vote at the Meeting, which will take place on June 15, 2021 at 9:00 p.m., EST, at Room 3106, Building B, Jianwai SOHO, Chaoyang District, Beijing, 100022, People’s Republic of China.

Stockholders are being asked to consider and vote upon proposals to (i) re-elect seven directors to the Board to serve until their successors are duly elected and qualified at the 2022 annual meeting of stockholders or until their earlier resignation or removal, and (ii) ratify the appointment of CZD as our independent registered public accounting firm for the fiscal year ending June 30, 2021.

This proxy statement also gives you information on the proposals so that you can make an informed decision. You should read it carefully. Your vote is important. You are encouraged to submit your proxy card as soon as possible after carefully reviewing this proxy statement.

### Who can vote at the Meeting?

Stockholders who owned shares of our common stock on the Record Date may attend and vote at the Meeting. There were 4,009,288 shares of common stock outstanding on the Record Date. All shares of common stock shall have one vote per share. Information about the stockholdings of our directors, executive officers, and significant stockholders is contained in the section entitled “Security Ownership of Certain Beneficial Owners and Management” beginning on page 12 of this proxy statement.

### What is the proxy card?

The card enables you to appoint Yanzeng An as your representative at the Meeting. By completing and returning the proxy card, you are authorizing this person to vote your shares at the Meeting in accordance with your instructions on the proxy card. This way, your shares will be voted whether or not you attend the Meeting. Even if you plan to attend the Meeting, it is strongly recommended to complete and return your proxy card before the Meeting date just in case your plans change. If a proposal comes up for vote at the Meeting that is not on the proxy card, the proxy will vote your shares, under your proxy, according to his best judgment.

### How does the Board recommend that I vote?

Our Board unanimously recommends that stockholders vote “FOR” each of the director nominees listed in proposal No. 1 and “FOR” proposal No. 2.

### What is the difference between holding shares as a stockholder of record and as a beneficial owner?

Certain of our stockholders hold their shares in an account at a brokerage firm, bank, or other nominee holder, rather than holding share certificates in their own name. As summarized below, there are some distinctions between shares held of record and those owned beneficially.

#### *Stockholder of Record/Registered Stockholders*

If, on the Record Date, your shares were registered directly in your name with our transfer agent, Transshare Corporation, you are a “stockholder of record” who may vote at the Meeting, and we are sending these proxy materials directly to you. As the stockholder of record, you have the right to direct the voting of your shares by returning the enclosed proxy card to us or to vote in person at the Meeting. Whether or not you plan to attend the Meeting, please complete, date, and sign the enclosed proxy card to ensure that your vote is counted.

#### *Beneficial Owner*

If, on the Record Date, your shares were held in an account at a brokerage firm or at a bank or other nominee holder, you are considered the beneficial owner of shares held “in street name,” and these proxy materials are being forwarded to you by your broker or nominee who is considered the stockholder of record for purposes of voting at the Meeting. As the beneficial owner, you have the right to direct your broker on how to vote your shares and to attend the Meeting. However, since you are not the stockholder of record, you may not vote these shares in person at the Meeting unless you receive a valid proxy from your brokerage firm, bank, or other nominee holder. To obtain a valid proxy, you must make a special request of your brokerage firm, bank, or other nominee holder. If you do not make this request, you can still vote by using the voting instruction card enclosed with this proxy statement; however, you will not be able to vote in person at the Meeting.

### **How do I vote?**

If you were a stockholder of record of the Company's common stock on the Record Date, you may vote in person at the Meeting or by submitting a proxy. Each share of common stock that you own in your name entitles you to one vote, in each case, on the applicable proposals.

(1) **You may submit your proxy by mail.** You may submit your proxy by mail by completing, signing, and dating your proxy card and returning it in the enclosed, postage-paid, and addressed envelope. If we receive your proxy card prior to the Meeting and if you mark your voting instructions on the proxy card, your shares will be voted:

- as you instruct, and
- according to the best judgment of the proxies if a proposal comes up for a vote at the Meeting that is not on the proxy card.

We encourage you to examine your proxy card closely to make sure you are voting all of your shares in the Company.

If you return a signed card, but do not provide voting instructions, your shares will be voted:

- FOR each nominee for director;
- FOR the selection of CZD as our independent registered public accounting firm for the fiscal year ending June 30, 2021; and
- According to the best judgment of Yanzeng An if a proposal comes up for a vote at the Meeting that is not on the proxy card.

(2) **You may vote in person at the Meeting.** We will pass out written ballots to any stockholder of record who wants to vote at the Meeting.

### **If I plan on attending the Meeting, should I return my proxy card?**

Yes. Whether or not you plan to attend the Meeting, after carefully reading and considering the information contained in this proxy statement, please complete and sign your proxy card, and then return the proxy card in the pre-addressed, postage-paid envelope provided herewith as soon as possible, so your shares may be represented at the Meeting.

### **May I change my mind after I return my proxy?**

Yes. You may revoke your proxy and change your vote at any time before the polls close at the Meeting. You may do this by:

- sending a written notice to the Secretary of the Company at the Company's executive offices stating that you would like to revoke your proxy of a particular date;
- signing another proxy card with a later date and returning it to the Secretary before the polls close at the Meeting; or
- attending the Meeting and voting in person.

### **What does it mean if I receive more than one proxy card?**

You may have multiple accounts at the transfer agent and/or with brokerage firms. Please sign and return all proxy cards to ensure that all of your shares are voted.

**What happens if I do not indicate how to vote my proxy?**

Signed and dated proxies received by the Company without an indication of how the stockholder desires to vote on a proposal will be voted in favor of each director and proposal presented to the stockholders.

**Will my shares be voted if I do not sign and return my proxy card?**

If you do not sign and return your proxy card, your shares will not be voted unless you vote in person at the Meeting.

**What vote is required to re-elect the director nominees as directors of the Company?**

The re-election of each nominee for director requires the affirmative vote of a plurality of the shares of common stock represented in person or by proxy and entitled to vote in the re-election of directors at the Meeting.

**How many votes are required to appoint CZD as the Company's independent registered public accounting firm for fiscal year ending June 30, 2021?**

The proposal to appoint CZD to serve as our independent registered public accounting firm for the fiscal year ending June 30, 2021 requires the affirmative vote of a majority of the votes cast at the Meeting by the holders of shares of common stock entitled to vote.

**Is my vote kept confidential?**

Proxies, ballots, and voting tabulations identifying stockholders are kept confidential and will not be disclosed, except as may be necessary to meet legal requirements.

**Where do I find the voting results of the Meeting?**

We will announce voting results at the Meeting and also file a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (the "SEC") reporting the voting results.

**Who can help answer my questions?**

You can contact Yuying Zhang at (+86) 10-58693193 or by sending a letter to the offices of the Company at Room 1001, Building T5, DaZu Square, Daxing District, Beijing 100176, People's Republic of China with any questions about proposals described in this proxy statement or how to execute your vote.

## General Information about the Meeting and Voting

*We are furnishing this proxy statement to you, as a stockholder of Shineco, Inc., as part of the solicitation of proxies by our Board for use at the Meeting to be held on June 15, 2021, and any adjournment or postponement thereof. This proxy statement is first being furnished to stockholders on or about May 12, 2021. This proxy statement provides you with information you need to know to be able to vote or instruct your proxy how to vote at the Meeting.*

<b>Date, Time, and Place of the Meeting</b>	The Meeting will be held on June 15, 2021, at 9:00 p.m., EST, at Room 3106, Building B, Jianwai SOHO, Chaoyang District, Beijing, 100022, People's Republic of China, or such other date, time, and place to which the Meeting may be adjourned or postponed.
<b>Purpose of the Meeting</b>	<p>At the Meeting, the Company will ask stockholders to consider and vote upon the following proposals:</p> <ol style="list-style-type: none"><li>1. Re-elect seven directors to the Board to serve until their successors are duly elected and qualified at the 2022 annual meeting of stockholders or until their earlier resignation or removal; and</li><li>2. Ratify the appointment of CZD as the independent registered public accounting firm of the Company for the fiscal year ending June 30, 2021.</li></ol>
<b>Record Date and Voting Power</b>	Our Board fixed the close of business on April 30, 2021, as the record date for the determination of the outstanding shares of common stock entitled to notice of, and to vote on, the matters presented at the Meeting. As of the Record Date, there were 4,009,288 shares of common stock outstanding. Each share of common stock entitles the holder thereof to one vote. Accordingly, a total of 4,009,288 votes may be cast at the Meeting.
<b>Quorum and Required Vote</b>	<p>A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present at the meeting if a majority of the common stock outstanding and entitled to vote at the Meeting is represented in person or by proxy. Abstentions and broker non-votes (i.e., shares held by brokers on behalf of their customers, which may not be voted on certain matters because the brokers have not received specific voting instructions from their customers with respect to such matters) will be counted solely for the purpose of determining whether a quorum is present at the Meeting.</p> <p>Proposal No. 1 (re-election of seven directors) requires the affirmative vote of a plurality of the shares of common stock represented in person or by proxy and entitled to vote in the re-election of directors at the Meeting. Abstentions and broker non-votes will have no effect on the re-election of directors; and</p> <p>Proposal No. 2 (ratification of appointment of CZD to serve as our independent registered public accounting firm for fiscal year ending June 30, 2021) requires the affirmative vote of the majority of the shares present in person or represented by proxy at the Meeting and entitled to vote thereon. Abstentions and broker non-votes will have no direct effect on the outcome of this proposal.</p>
<b>Revocability of Proxies</b>	Any proxy may be revoked by the person giving it at any time before it is voted. A proxy may be revoked by (A) sending to our Secretary, at Shineco, Inc., Room 1001, Building T5, DaZu Square, Daxing District, Beijing 100176, People's Republic of China, either (i) a written notice of revocation bearing a date later than the date of such proxy or (ii) a subsequent proxy relating to the same shares, or (B) by attending the Meeting and voting in person.
<b>Proxy Solicitation Costs</b>	The cost of preparing, assembling, printing, and mailing this proxy statement and the accompanying form of proxy, and the cost of soliciting proxies relating to the Meeting, will be borne by the Company. If any additional solicitation of the holders of our outstanding shares of common stock is deemed necessary, we (through our directors and officers) anticipate making such solicitation directly. The solicitation of proxies by mail may be supplemented by telephone, telegram, and personal solicitation by officers, directors, and other employees of the Company, but no additional compensation will be paid to such individuals.
<b>No Right of Appraisal</b>	None of Delaware law, our Certificate of Incorporation, or our Bylaws provides for appraisal or other similar rights for dissenting stockholders in connection with any of the proposals to be voted upon at the Meeting. Accordingly, our stockholders will have no right to dissent and obtain payment for their shares.
<b>Who Can Answer Your Questions about Voting Your Shares</b>	You can contact Yuying Zhang at (+86) 10-58693193 or by sending a letter to the offices of the Company at Room 1001, Building T5, DaZu Square, Daxing District, Beijing 100176, People's Republic of China, with any questions about proposals described in this proxy statement or how to execute your vote.
<b>Principal Offices</b>	The principal executive offices of our Company are located at Room 1001, Building T5, DaZu Square, Daxing District, Beijing 100176, People's Republic of China. The Company's telephone number is (+86) -010-58693193.

### Proposal No. 1 — Re-Election of Directors

Our Board consists of seven directors, all of whom have been nominated by the Nominating and Corporate Governance Committee of our Board (the “Nominating Committee”) and approved by our Board to stand for re-election as directors of the Company. Unless such authority is withheld, proxies will be voted for the re-election of the persons named below, each of whom has been designated as a nominee. If, for any reason, any nominee/director becomes unavailable for re-election, the proxies will be voted for such substitute nominee(s) as the Board may propose.

We believe that the collective skills, experiences, and qualifications of our directors provide our Board with the expertise and experience necessary to advance the interests of our stockholders. While the Nominating Committee of our Board does not have any specific, minimum qualifications that must be met by each of our directors, the Nominating Committee uses a variety of criteria to evaluate the qualifications and skills necessary for each member of the Board. In addition to the individual attributes of each of our current directors described below, we believe that our directors should have the highest professional and personal ethics and values, consistent with our longstanding values and standards. They should have broad experience at the policy-making level in business, exhibit commitment to enhancing stockholder value, and have sufficient time to carry out their duties and to provide insight and practical wisdom based on their past experience.

The director nominees recommended by the Board are as follows:

#### THE BOARD RECOMMENDS THE RE-ELECTION OF THESE NOMINEES:

<b>Name</b>	<b>Age</b>	<b>Director Since</b>	<b>Independent</b>	<b>Position</b>
<b>Yuying Zhang</b>	70	2011	No	Chairman and Director
<b>Sai (Sam) Wang</b>	36	2016	No	Chief Financial Officer and Director*
<b>Baolin Li</b>	66	2019	No	Director
<b>Jin Liu</b>	55	2020	Yes	Director
<b>Yanzeng An</b>	42	2019	Yes	Director
<b>Ning Chen</b>	51	2020	Yes	Director
<b>Harry Edelson</b>	86	2019	Yes	Director

\* Mr. Sai (Sam) Wang has been our CFO since 2015 and director since 2016.



## Nominee Information

**Yuying Zhang**  
Age: 70

Director since:

2011

**Principal Occupation:** Chairman and Director of the Company

**Business Experience:**

- Director of Tianjin Tenet Huatai Technological Development Co., Ltd. since 2003
- Chairman and CEO of Beijing Tenet-Jove Technological Development Co., Ltd. since December 2003
- Chairman of the Board of Beijing Huiyin Ansheng Asset Management Co., Ltd. from April 2014 to December 2014
- General Manager of Tianjin Balas Technological Development Co., Ltd. from 1995 to December 2003
- Former Deputy director at the Army Institute of Integrative Medicine
- Executive Director and Deputy General Manager at Shan Haidan Pharmaceutical Group from 1991 to 1994

**Skills and Expertise:**

- knowledge and extensive experience in research and development and management

**Sai (Sam) Wang**  
Age: 36

Director since:

2016

**Principal Occupation:** Chief Financial Officer of the Company

**Business Experience:**

- Financial Controller of the Company from 2011 and 2015
- Supervisory director of Shineco Zhisheng (Beijing) Bio-Technology Co., Ltd. since 2014
- General Manager of Qingdao Yinghuanhai International Logistics Co., Ltd. since 2012
- Manager of Corporate Finance of Citibank in Shenzhen from 2008 to 2011

**Skills and Expertise:**

- In-depth experience with our financial matters
- Profound knowledge of our industry

**Baolin Li**  
Age: 66

Director since:

2019

**Principal Occupation:** Director of the Company

**Business Experience:**

- Legal Representative of Shanghai Jiazheng Investment Management Co., Ltd. since July 2013
- Legal Representative of Yushe County Linbao Bio-energy Technology Co., Ltd. since February 2018
- Legal Representative of Yushe County Guangyuan Forest Development Co., Ltd. since June 2018

**Skills and Expertise:**

- Great experience in biological industry

**Jin Liu**  
Age: 55

Director since:

2019

**Principal Occupation:** Executive Vice-President of China Science & Merchants Investment Management Group

**Business Experience:**

- Independent Director of Jilin JLU Communication Design Institute Co., Ltd. (SHE: 300597) since 2017
- Executive Vice-President of China Science & Merchants Investment Management Group since 2014

**Skills and Expertise:**

- Expertise in risk control, information disclosure, and financial management of domestic and foreign listed companies

**Principal Occupation:** Partner and lawyer at Beijing Bright Law Firm

**Yanzeng An**  
Age: 42  
Director since:

2019

**Business Experience:**

- Partner and lawyer at Beijing Bright Law Firm since 2016
- Criminal trial work at Beijing Shijingshan District Court from 2008 to 2015
- Civil trial work at Dezhou Court in Shandong Province from 2002 to 2005

**Skills and Expertise:**

- Quality experience in the legal field

**Ning Chen**  
Age: 51  
Director since:

2019

**Principal Occupation:** President of Jicai Capital Management (Beijing) Co., Ltd

**Business Experience:**

- President of Jicai Capital Management (Beijing) Co., Ltd.
- CEO of Jijing Caihua Capital Management Co., Ltd. from October 2017 to November 2018
- Executive Vice President of China Science and Merchants Capital Management Group from June 2014 to October 2017
- Vice President of Runjia Huasheng Investment Fund Management Co., Ltd. from September 2011 to June 2014

**Skills and Expertise:**

- Great experience in financial management.

**Principal Occupation:** President of Edelson Technology, Inc.**Business Experience:**

- Founder of Edelson Technology Partners
- President of Edelson Technology, Inc., a company involved in consulting, fundraising, M&A, and investments since 1980
- Served on over 150 boards of directors (12 as chairman)
- director of four private companies, Airwire, PogoTec, eChinaCash, and Pathway Genomics, and one public company, China Gerui

**Skills and Expertise:**

- Decades of experience on Wall Street and various venture capital ventures
- SPAC experience, vast board experience, and participated in numerous M&A transactions

**Corporate Governance Practices and Policies****Board and Committee Independence**

The Board determines whether each of our directors is considered independent. For a director to be considered independent, the director must meet the bright-line independence standards under the Nasdaq listing standards. The Board must also affirmatively determine that, in its opinion, each director has no relationship that would interfere with the directors' exercise of independent judgment in carrying out the director's responsibilities. In addition to the Nasdaq listing standards, the Board will consider all relevant facts and circumstances in determining whether a director is independent. There are no family relationships among any of our directors and executive officers. The Board has determined that the following nominees satisfy the independence requirements of Nasdaq: Jin Liu, Yanzeng An, Ning Chen, and Harry Edelson.

**Board Committees and Meetings**

The Board held five meetings during fiscal year 2020. No director attended fewer than 75% the aggregate number of all meetings of the Board and committees on which he or she served during fiscal year 2020. All of the Company's directors attended last year's annual meeting of stockholders either in person or by conference call. The Company expects the directors to attend the Meeting either in person or by conference call.

## Board Committees

The Board has created three standing committees: an Audit Committee, a Compensation Committee, and a Nominating Committee. The Board has adopted a formal, written charter for each of the committees under which each committee operates. The charters can be found in the Corporate Governance section of the Investor Relations tab on the Company's website at <http://tianyiluobuma.com>. As a matter of routine corporate governance, each committee intends to review its charter and practices on an annual basis to determine whether its charter and practices are consistent with listing standards of Nasdaq.

### Committee Composition

<b>Director</b>	<b>Audit</b>	<b>Compensation</b>	<b>Nominating</b>
<b>Jin Liu</b>	(1)(2)(3)	(1)	(1)
<b>Yanzeng An</b>	(1)		(1)(2)
<b>Harry Edelson</b>	(1)	(1)	
<b>Ning Chen</b>		(1)(2)	(1)

(1) Committee member;

(2) Committee chair;

(3) Our board has determined that we have at least one "audit committee financial expert," as defined by the rules and regulations of the SEC and that is Jin Liu.

### Audit Committee

Upon re-election, Jin Liu, Yanzeng An, and Harry Edelson will be members of our Audit Committee of the Board (the "Audit Committee"), where Mr. Jin Liu shall serve as the chairman. All members of our Audit Committee satisfy the independence standards promulgated by the SEC and by Nasdaq as such standards apply specifically to members of Audit Committees.

We have adopted and approved a charter for the Audit Committee. In accordance with our Audit Committee Charter, our Audit Committee shall perform several functions, including:

- evaluates the independence and performance of, and assesses the qualifications of, our independent auditor, and engages such independent auditor;
- approves the plan and fees for the annual audit, quarterly reviews, tax, and other audit-related services, and approves in advance any non-audit service to be provided by the independent auditor;
- monitors the independence of the independent auditor and the rotation of partners of the independent auditor on our engagement team as required by law;
- reviews the financial statements to be included in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and reviews with management and the independent auditors the results of the annual audit and reviews of our quarterly financial statements;
- oversees all aspects of our systems of internal accounting control and corporate governance functions on behalf of the Board;
- reviews and approves in advance any proposed related-party transactions and reports to the full Board on any approved transactions; and
- provides oversight assistance in connection with legal, ethical, and risk management compliance programs established by management and the Board, including Sarbanes-Oxley Act implementation, and makes recommendations to the Board regarding corporate governance issues and policy decisions.

It is determined that Mr. Jin Liu possesses accounting or related financial management experience that qualifies him as an “audit committee financial expert” as defined by the rules and regulations of the SEC.

The Audit Committee held two meetings in fiscal year 2020.

#### **Compensation Committee**

Upon re-election, Jin Liu, Harry Edelson, and Ning Chen will be members of our Compensation Committee of the Board (the “Compensation Committee”) and Mr. Ning Chen shall serve as the chairman. All members of our Compensation Committee are qualified as independent under the current definition promulgated by Nasdaq. We have adopted a charter for the Compensation Committee. In accordance with the Compensation Committee’s Charter, the Compensation Committee is responsible for overseeing and making recommendations to the Board regarding the salaries and other compensation of our executive officers and general employees and providing assistance and recommendations with respect to our compensation policies and practices.

The Compensation Committee held four meetings in fiscal year 2020.

#### **Nominating Committee**

Upon re-election, Jin Liu, Yanzeng An, and Harry Edelson will be the members of our Nominating Committee, where Ms. Yanzeng An shall serve as the chairwoman. All members of our Nominating and Governance Committee are qualified as independent under the current definition promulgated by Nasdaq. Our Board adopted and approved a charter for the Nominating Committee. In accordance with the Nominating Committee’s Charter, the Nominating Committee is responsible to identify and propose new potential director nominees to the board of directors for consideration and review our corporate governance policies.

The Nominating Committee held four meetings in fiscal year 2020.

#### **Board Role in Risk Oversight**

Our Audit Committee is primarily responsible for overseeing our risk management processes on behalf of the Board, including with respect to cybersecurity risks. The Audit Committee receives reports from management on at least a quarterly basis regarding management’s assessment of risks to the Company.

In addition, the Audit Committee reports regularly to our Board, which also monitors our risk profile. The Audit Committee and the Board focus on the most significant risks we face and our general risk management strategies, while our management team coordinates responses to day-to-day risks.

#### **Code of Conduct and Ethics**

We have adopted a code of conduct and ethics (the “Code of Ethics”) applicable to our directors, officers, and employees in accordance with applicable federal securities laws and Nasdaq rules. The Code of Ethics is publicly available in the Corporate Governance section of the Investor Relations tab on the Company’s website at <http://tianyiluobuma.com>. We intend to post any amendments to or waivers from the Code of Ethics that apply to our principal executive officer, principal financial officer, and principal accounting officer, or persons performing similar functions, on our website.

#### **Family Relationships**

There are no family relationships between or among the director nominees or other executive officers of the Company.

## **Legal Proceedings Involving Officers and Directors**

To the knowledge of the Company after reasonable inquiry, no director nominee or executive officers during the past 10 years, or any promoter who was a promoter at any time during the past five fiscal years, has (1) been subject to a petition under the Federal bankruptcy laws or any state insolvency law was filed by or against, or a receiver, fiscal agent, or similar officer was appointed by a court for the business or property of such person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing; (2) been convicted in a criminal proceeding or is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses); (3) been the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities: (i) acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings, and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity; (ii) engaging in any type of business practice; or (iii) engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of Federal or State securities laws or Federal commodities laws; (4) been the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described in paragraph (3)(i) of this section, or to be associated with persons engaged in any such activity; (5) been found by a court of competent jurisdiction in a civil action or by the SEC to have violated any Federal or State securities law, and the judgment in such civil action or finding by the SEC has not been subsequently reversed, suspended, or vacated; (6) been found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated; (7) been the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of: (i) any Federal or State securities or commodities law or regulation; or (ii) any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or (iii) any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or (8) been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Securities Exchange Act of 1934, as amended, or the "Exchange Act" (15 U.S.C. 78c(a)(26)), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29)), or any equivalent exchange, association, entity, or organization that has disciplinary authority over its members or persons associated with a member.

There are no material pending legal proceedings to which any of the individuals listed above is party adverse to the Company or any of its subsidiaries or has a material interest adverse to the Company or any of its subsidiaries.

## **Stockholder Communications with the Board**

We have not implemented a formal policy or procedure by which our stockholders can communicate directly with our Board. Nevertheless, every effort will be made to ensure that the views of stockholders are heard by the Board, and that appropriate responses are provided to stockholders in a timely manner. During the upcoming year, our Board will continue to monitor whether it would be appropriate to adopt such a process.

## **Director Compensation**

During the fiscal year ended June 30, 2020, we paid our independent directors an annual cash retainer of \$10,000, except Harry Edelson who received \$36,000. In the future, we may also provide stock, option, or other equity-based incentives to our directors for their service. We also reimbursed our directors for any out-of-pocket expenses incurred by them in connection with their services provided in such capacity.

The following table reflects all compensation awarded to, earned by, or paid to our directors for the fiscal year ended June 30, 2020. Directors who are also officers do not receive any additional compensation for their services as directors.

Name	Fees earned in cash <sup>(1)</sup> ( $\text{\$}$ )	Stock Awards ( $\text{\$}$ )	Option Awards ( $\text{\$}$ )	Non-Equity Incentive Plan Compensation ( $\text{\$}$ )	Non-Qualified Deferred Compensation Earnings ( $\text{\$}$ )	All Other Compensation ( $\text{\$}$ )	Total ( $\text{\$}$ )
Yuying Zhang	120,000	—	—	—	—	21,130	141,130
Sai (Sam) Wang	99,600	—	—	—	—	—	99,600
Baolin Li	10,000	—	—	—	—	—	10,000
Jin Liu	10,000	—	—	—	—	—	10,000
Yanzeng An	10,000	—	—	—	—	—	10,000
Ning Chen	10,000	—	—	—	—	—	10,000
Harry Edelson	36,000	—	—	—	—	—	36,000

(1) All cash compensation was paid in RMB. The amounts in the foregoing table have been converted into U.S. Dollar at the conversion rate at RMB1 to US\$0.1466.

### Executive Officers

Our current executive officers are as follows:

Name	Age	Position
Ou Yang	38	Chief Executive Officer of the Company
Sai (Sam) Wang	36	Chief Financial Officer and Director of the Company

**Ou Yang**, has been our Chief Executive Officer since May 2021. From January 2020 to May 2021, Ms. Yang served as a partner of Wuhan Sinopharm Optical Valley Capital Management Co., Ltd., a subsidiary of China National Pharmaceutical Group Corporation and an equity investment institution focusing on the medical and healthcare field, and was responsible for the investment and post-investment management of the funds managed by the company. From May 2014 to December 2019, Ms. Yang worked at multiple fund management companies and investment companies under Northeast Securities Co., Ltd (SHE: 000686), in various roles, including general manager, deputy general manager, director, and member of investment committee, and was in charge of or participated in the investment of buyout funds in the United States and Europe. Ms. Yang obtained her bachelor's degree and master's degree in Finance from Jilin University School of Economics in 2006 and 2008, respectively.

**Sai (Sam) Wang**, became our Chief Financial Officer in February 2015 and Director since 2016. Mr. Wang has worked for Shineco, Inc. since 2011, where he served as Financial Controller until his appointment as our Chief Financial Officer. Mr. Wang has been the supervisory director of Shineco Zhisheng (Beijing) Bio-Technology Co., Ltd. since 2014. He has served as the General Manager of Qingdao Yinghuanhai International Logistics Co., Ltd. since 2012. Prior to joining Shineco, he worked for Citibank in Shenzhen from 2008 until 2011, where he served as Manager of Corporate Finance. Mr. Wang obtained a Masters in Commerce with a concentration in applied finance from the University of Queensland in 2010. In 2008, he received a bachelor's degree in Accounting from Griffith University in Australia. Mr. Wang was chosen as a director because he has profound knowledge of our industry and he is experienced with our financial matters.

### Executive Compensation

The following table sets forth the compensation paid by us during the fiscal years ended June 30, 2020 and 2019 for services performed on our behalf with respect to the persons who served as our named executive officers as of June 30, 2020 and for the fiscal year ended June 30, 2020. Our named executive officers were Mr. Yuying Zhang and Mr. Sai (Sam) Wang. Mr. Zhang served as our Chief Executive Officer and Mr. Wang serves as our Chief Financial Officer.

Name and Principal Position	Summary Compensation Table						
	Year Ended June 30,	Salary <sup>(1)</sup> ( $\text{\$}$ )	Bonus ( $\text{\$}$ )	Stock Awards ( $\text{\$}$ )	Option Awards ( $\text{\$}$ )	All Other Compensation ( $\text{\$}$ )	Total ( $\text{\$}$ )
Yuying Zhang <sup>(2)</sup> Chief Executive Officer	2020	120,000	—	—	—	21,130 <sup>(3)</sup>	141,130
	2019	120,000	—	—	—	18,180 <sup>(3)</sup>	138,180
Sai (Sam) Wang Chief Financial Officer	2020	99,600	—	—	—	—	99,600
	2019	99,600	—	—	—	—	99,600

(1) Salaries were paid in RMB.

(2) Mr. Zhang ceased to be our Chief Executive Officer on August 4, 2020.

(3) Mr. Zhang receives monthly payments for rent for his personal home and parking.

## Grants of Plan Based Awards in the Fiscal Year Ended June 30, 2020

During the fiscal year ended June 30, 2020, the Company has not adopted any incentive plan.

## Outstanding Equity Awards at Fiscal Year Ended June 30, 2020

There were no equity awards granted to our officers or directors in the year ended June 30, 2020.

## Employment Contracts, Termination of Employment, and Change-in-Control Arrangements

Under Chinese law, we may only terminate employment agreements without cause and without penalty by providing notice of non-renewal one month prior to the date on which the employment agreement is scheduled to expire. If we fail to provide this notice or if we wish to terminate an employment agreement in the absence of cause, then we are obligated to pay the employee one month's salary for each year we have employed the employee. We are, however, permitted to terminate an employee for cause without penalty to our company, where the employee has committed a crime or the employee's actions or inactions have resulted in a material adverse effect to us.

We currently have no contract, agreement, plan, or arrangement, whether written or unwritten, that provides for payments to our executive officers at, following, or in connection with any termination, including without limitation resignation, severance, retirement, or a constructive termination of a named executive officer, or a change in control of the Company or a change in the executive officer's responsibilities, with respect to each executive officer.

## Section 16(a) Compliance

Section 16(a) of the Exchange Act, requires our directors, officers, and persons who own more than 10% of our common stock to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other of our equity securities. To our knowledge, based solely on review of the copies of such reports furnished to us, as of the date of this proxy, all Section 16(a) filings applicable to officers, directors, and greater than 10% stockholders were made.

## Security Ownership of Certain Beneficial Owners and Management

The following table sets forth information regarding the beneficial ownership of our common stock by any person known to us to be the beneficial owner of more than 5% of the outstanding common stock, by directors and certain executive officers, and by all of our directors and executive officers as a group. Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she, or it possesses sole or shared voting or investment power over that security or has the right to acquire securities within 60 days, including options and warrants that are currently exercisable or exercisable within 60 days.

Unless otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all shares beneficially owned by them. The calculation of percentage of beneficial ownership is based on 4,009,288 shares of our common stock that were outstanding as of the Record Date.

<b>Name and Address of Beneficial Owner(1)</b>	<b>Number of Shares of Common Stock Beneficially Owned</b>	<b>Percentage of Outstanding Shares of Common Stock</b>
<b><i>Directors and Executive Officers of the Company:</i></b>		
Ou Yang	—	—
Yuying Zhang	536,703(2)	13.39%
Sai (Sam) Wang	517,294(3)	12.90%
Baolin Li	99,565	2.48%
Jin Liu	—	—
Yanzeng An	—	—
Ning Chen	—	—
Harry Edelson	—	—
All directors and executive officers as a group (eight individuals)	1,164,512	29.05%
<b><i>Five Percent or More Stockholder:</i></b>		
Wei Chang	227,537	5.68%

(1) Unless otherwise indicated, the business address of each of the persons and entities is Room 1001, Building T5, DaZu Square, Daxing District, Beijing, People's Republic of China 100176.

(2) Includes 409,687 shares of common stock, of which Yuying Zhang may exercise voting rights as a stockholder of the Company at his sole discretion pursuant to certain voting rights proxy agreements.

(3) Includes 434,000 shares of common stock, of which Sai (Sam) Wang may exercise voting rights as a stockholder of the Company at his sole discretion pursuant to certain voting rights proxy agreements.



## Certain Relationships and Related Party Transactions

### Review, Approval, or Ratification of Related Party Transactions

Our Audit Committee is responsible for reviewing and approving all related party transactions that are required to be disclosed under the applicable rules of the SEC and Nasdaq, when appropriate, and authorizing or ratifying all such transactions in accordance with written policies and procedures established by our board of directors from time to time. The Audit Committee may approve or ratify related party transaction only if it determines in good faith that under all the circumstances, the transaction is fair to us.

A director may vote in respect of any contract or transaction in which he or she is interested, provided, however that the nature of the interest of any director in any such contract or transaction shall be disclosed by him or her at or prior to its consideration and any vote on that matter. A general notice or disclosure to the directors or otherwise contained in the minutes of a meeting or a written resolution of the directors or any committee thereof of the nature of a director's interest shall be sufficient disclosure and after such general notice it shall not be necessary to give special notice relating to any particular transaction. A director may be counted for a quorum upon a motion in respect of any contract or arrangement which he or she shall make with our company, or in which he or she is so interested and may vote on such motion.

We have a policy under which we are prohibited from making or renewing any personal loan to our executive officers or directors in accordance with Section 13(k) of the Exchange Act. The related party transactions with Yuying Zhang, our director and former Chief Executive Officer, described in this section occurred prior to adoption of this policy, and as such, these transactions were not subject to such prohibition. As of date of the Annual Report on Form 10-K filed on September 28, 2020 with the SEC, all outstanding amounts due from any loans to executive officers or directors have been collected in full.

### Transactions

Members of the current management team are the owners of the VIEs in the PRC.

### Due from Related Parties

The Company had previously made temporary advances to certain stockholders (listed below) of the Company and to other entities that are either owned by family members of those stockholders or to other entities that the Company has investments in. Those advances are due on demand, non-interest bearing.

As of June 30, 2020 and 2019, the outstanding amounts due from related parties consist of the following:

	<u>June 30, 2020</u>	<u>June 30, 2019</u>
Bin Yang	\$ 42,434	\$ 43,688
Beijing Huiyinansheng Asset Management Co., Ltd <sup>(1)</sup>	21,217	21,873
Beijing Shengguang Tianyi Clothing Co., LTD <sup>(2)</sup>	—	63,911
Qiwei Wang	57,288	58,981
<b>Total due from related parties</b>	<b>\$ 120,939</b>	<b>\$ 188,453</b>

(1) This company is wholly owned by one of the Company's senior management.

(2) This company is wholly owned by one of the Company's stockholders.

## Due to Related Parties

As of June 30, 2020 and 2019, the Company had related party payables of US\$1,355,919 and US\$234,500, respectively, mainly due to the principal stockholders or certain relatives of the stockholders of the Company who lend funds for the Company's operations. The payables are unsecured, non-interest bearing, and due on demand.

	<u>June 30, 2020</u>	<u>June 30, 2019</u>
Yang Wu <sup>(1)</sup>	\$ 90,598	\$ 93,275
Sai (Sam) Wang <sup>(2)</sup>	90,629	8,738
Jiping Chen	3,024	989
Yuying Zhang	-	2,913
Guocong Zhou <sup>(3)</sup>	648,308	-
Baolin Li	353,619	-
Min Zhao <sup>(4)</sup>	169,741	128,585
Total due to related parties	<u>\$ 1,355,919</u>	<u>\$ 234,500</u>

(1) Yang Wu is the wife of Weixing Yin, one of our former Directors.

(2) Sai (Sam) Wang is our Chief Financial Officer and Director. The Company paid Mr. Wang \$90,629 for the related party payables in the fiscal year ended June 30, 2020.

(3) Guocong Zhou ceased to be our Chief Executive Officer on May 5, 2021.

(4) Min Zhao is the wife of Yuying Zhang, our Chair of the Board and former Chief Executive Officer.

## Sales to Related Parties

For the fiscal years ended June 30, 2020 and 2019, the Company recorded sales to Shaanxi Pharmaceutical Group Pai'ang Medicine Co. Ltd., a related party, of US\$2,990,910 and US\$3,405,982, respectively. As of June 30, 2020 and 2019, the balance of accounts receivable due from Shaanxi Pharmaceutical Group Pai'ang Medicine Co. Ltd. was US\$1,567,160 and US\$2,706,111, respectively.

## Proposal No. 2 — Ratification of Appointment of Independent Registered Public Accounting Firm

While stockholder ratification of the Company's independent registered public accountants is not required by our Certificate of Incorporation, Bylaws, or otherwise, the Audit Committee and management believe that it is desirable and a matter of good corporate practice for stockholders to ratify the Company's selection of the independent registered public accountants. The Audit Committee has selected CZD to serve as the independent registered public accounting firm of the Company for the fiscal year ending June 30, 2021. Therefore, we are requesting that stockholders approve the proposal to ratify the appointment of CZD as our independent registered public accounting firm.

The Audit Committee values the input of our stockholders. In the event that stockholders do not approve this proposal, the Audit Committee may reconsider this appointment.

We have been advised by CZD that neither the firm nor any of its associates had any relationship during the last fiscal year with our Company other than the usual relationship that exists between independent registered public accountant firms and their clients. Representatives of CZD are not expected to attend the Meeting in person and therefore are not expected to be available to respond to any questions. As a result, representatives of CZD will not make a statement at the Meeting.

**THE BOARD RECOMMENDS THAT YOU VOTE “FOR” RATIFYING THE APPOINTMENT OF CZD TO SERVE AS THE COMPANY’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING JUNE 30, 2021.**

**Change of Independent Registered Public Accounting Firm**

As previously disclosed in the Current Report on Form 8-K filed with the SEC on January 22, 2019 (the “January 2019 Form 8-K”), on January 15, 2019, the Company decided to change its independent registered public accounting firm for the annual report of the fiscal year ended June 30, 2019 and the remainder of the fiscal year ended June 30, 2019. On January 15, 2019, the Board approved the appointment of CZD as the Company’s independent registered public accounting firm for the Company’s fiscal year ended June 30, 2019 and the dismissal of Wei, Wei & Co., LLP (“Wei Wei”) from that role, each effective as of January 15, 2019.

During the fiscal years ended June 30, 2018 and 2017, and the subsequent interim period through January 22, 2019, there were (i) no “disagreements” (as that term is described in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Wei Wei on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to Wei Wei’s satisfaction, would have caused Wei Wei to make reference thereto in their reports, and (ii) no “reportable events” (as that term is described in Item 304(a)(1)(v) of Regulation S-K) except that Wei Wei advised the Company of material weaknesses related to ineffective disclosure controls and procedures as the Company did not have a Chief Financial Officer that is familiar with the accounting and reporting requirements of a U.S. publicly-listed company, and it did not have U.S. GAAP full-time qualified personnel in the accounting department to monitor the recording of the daily transactions and the lack of segregation of duties for accounting personnel who prepared and reviewed the journal entries during the fiscal years ended June 30, 2018 and 2017.

The Company provided Wei Wei with a copy of the disclosures made within the January 2019 Form 8-K and requested that Wei Wei furnish a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with such disclosures. A copy of Wei Wei’s letter, dated January 22, 2019, was filed as Exhibit 16.1 to the January 2019 Form 8-K.

During the fiscal year ended June 30, 2018, and the subsequent interim period through January 15, 2019, neither the Company nor anyone on its behalf consulted with CZD regarding (i) the application of accounting principles to a specified transaction, (ii) the type of audit opinion that might be rendered on the Company’s financial statements by CZD, in either case where written or oral advice provided by CZD would be an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issues, or (iii) any other matter that was the subject of a disagreement between us and our former auditor, Wei Wei or was a reportable event (as described in Items 304(a)(1)(iv) or Item 304(a)(1)(v) of Regulation S-K, respectively).

**Fees Paid to the Independent Registered Public Accounting Firm**

Aggregate fees billed to the Company for services rendered by CZD for the fiscal years ended June 30, 2020 and 2019 were:

	2020	2019
Audit Fees <sup>(1)</sup>	\$ 195,000	\$ 195,000
Audit-Related Fees <sup>(2)</sup>	—	—
Tax Fees <sup>(3)</sup>	—	—
All Other Fees <sup>(4)</sup>	—	—
<b>Total Fees</b>	<b>\$ 195,000</b>	<b>\$ 195,000</b>

(1) **Audit Fees** – This category includes the audit of our annual financial statements, review of financial statements included in our Quarterly Reports on Form 10-Q, and services that are normally provided by independent auditors in connection with statutory and regulatory filings or the engagement for fiscal years. This category also includes advice on audit and accounting matters that arose during, or as a result of, the audit or the review of interim financial statements.

(2) **Audit-Related Fees** – This category consists of assurance and related services by our independent auditor that are reasonably related to the performance of the audit or review of our financial statements and are not reported above under “Audit Fees.” The services for the fees disclosed under this category include consultation regarding our correspondence with the SEC.

(3) **Tax Fees** – This category consists of professional services rendered by our independent auditors for tax compliance and tax advice. The services for the fees disclosed under this category include tax return preparation and technical tax advice.

(4) **All Other Fees** – This category consists of fees for other miscellaneous items such as travel and out-of-pocket expenses.

## **Policies and Procedures Relating to Approval of Services by our Independent Registered Public Accountants**

The Audit Committee is solely responsible for the approval in advance of all audit and permitted non-audit services to be provided by our independent registered public accounting firms (including the fees and other terms thereof), subject to the de minimus exceptions for non-audit services provided by Section 10A(i)(1)(B) of the Exchange Act, which services are subsequently approved by the Audit Committee prior to the completion of the audit. None of the fees listed above are for services rendered pursuant to such de minimus exceptions.

The Audit Committee has established its pre-approval policies and procedures, pursuant to which the Audit Committee approved the foregoing audit, tax, and non-audit services provided by CZD in the fiscal years ended June 30, 2020 and 2019. Consistent with the Audit Committee's responsibility for engaging our independent auditors, all audit and permitted non-audit services require pre-approval by the Audit Committee. The full Audit Committee approves proposed services and fee estimates for these services. One or more independent directors serving on the Audit Committee may be delegated by the full Audit Committee to pre-approve any audit and non-audit services. Any such delegation shall be presented to the full Audit Committee at its next scheduled meeting. Pursuant to these procedures, the Audit Committee approved the foregoing audit services provided by CZD.

### **Audit Committee Report**

The primary purpose of the Audit Committee is to assist the Board in fulfilling its responsibility to oversee our financial reporting activities. The Audit Committee is responsible for reviewing with both our independent registered public accounting firm and management, our accounting and reporting principles, policies and practices, and our accounting, financial, and operating controls and staff. The Audit Committee has reviewed and discussed our audited financial statements with management, and has discussed with our independent registered public accounting firm the matters required to be discussed by the Public Company Accounting Oversight Board's (the "PCAOB") Rule 3200T. Additionally, the Audit Committee has received the written disclosures and the letter from our independent registered public accounting firm, as required by the applicable requirements of the PCAOB, and has discussed with the independent registered public accounting firm's independence. Based upon such review and discussion, the Audit Committee recommended to the Board that the audited financial statements be included in our Annual Report on Form 10-K for the last fiscal year ended June 30, 2020 for filing with the SEC. The Audit Committee has also approved, subject to stockholders' ratification, the appointment of Centurion ZD CPA & Co. to serve as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2021.

Audit Committee  
Jin Liu  
Yanzeng An  
Harry Edelson

*The information contained in this proxy statement with respect to the Audit Committee's report above and the independence of the members of the Audit Committee shall not be deemed to be "soliciting material" or to be "filed" with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference in such filing.*

## Other Matters

Our Board knows of no other matter to be presented at the Meeting. If any additional matter should properly come before the Meeting, it is the intention of the persons named in the enclosed proxy to vote such proxy in accordance with their judgment on any such matters.

## Other Important Information

### Deadline for Submission of Stockholder Proposals for 2022 Annual Meeting of Stockholders

For any proposal to be considered for inclusion in our proxy statement and form of proxy for submission to the stockholders at our 2022 Annual Meeting of Stockholders, it must be submitted in writing and comply with the requirements of Rule 14a-8 of the Exchange Act. Such proposals must be received by the Company at its offices at Room 1001, Building T5, DaZu Square, Daxing District, Beijing 100176, People's Republic of China, Attention: Chief Executive Officer, no later than January 3, 2022.

If we are not notified of a stockholder proposal within a reasonable time prior to the time we send our proxy statement for our 2022 Annual Meeting of Stockholders, our Board will have discretionary authority to vote on the stockholder proposal, even though the stockholder proposal is not discussed in the proxy statement. In order to curtail any controversy as to the date on which a stockholder proposal was received by us, it is suggested that stockholder proposals be submitted by certified mail, return receipt requested, and be addressed to Shineco, Inc., Room 1001, Building T5, DaZu Square, Daxing District, Beijing 100176, People's Republic of China, Attention: Chief Executive Officer. Notwithstanding, the foregoing shall not affect any rights of stockholders to request inclusion of proposals in our proxy statement pursuant to Rule 14a-8 under the Exchange Act nor grant any stockholder a right to have any nominee included in our proxy statement.

### Proxy Solicitation

The solicitation of proxies is made on behalf of the Board and we will bear the cost of soliciting proxies. The transfer agent and registrar for our common stock, Transhare Corporation, as a part of its regular services and for no additional compensation other than reimbursement for out-of-pocket expenses, has been engaged to assist in the proxy solicitation. Proxies may be solicited through the mail and through telephonic or telegraphic communications to, or by meetings with, stockholders or their representatives by our directors, officers, and other employees who will receive no additional compensation therefor. We may also retain a proxy solicitation firm to assist us in obtaining proxies by mail, facsimile, or email from record and beneficial holders of shares for the Meeting. If we retain a proxy solicitation firm, we expect to pay such firm reasonable and customary compensation for its services, including out-of-pocket expenses.

We request persons such as brokers, nominees, and fiduciaries holding stock in their names for others, or holding stock for others who have the right to give voting instructions, to forward proxy material to their principals and to request authority for the execution of the proxy. We will reimburse such persons for their reasonable expenses.

### Annual Report

The Annual Report is being sent with this proxy statement to each stockholder and is available at <http://tianyiluobuma.com> as well as on the SEC's website at [www.sec.gov](http://www.sec.gov). The Annual Report contains our audited financial statements for the fiscal year ended June 30, 2020. The Annual Report, however, is not to be regarded as part of the proxy soliciting material.

### Delivery of Proxy Materials to Households

Only one copy of this proxy statement and one copy of our Annual Report are being delivered to multiple registered stockholders who share an address unless we have received contrary instructions from one or more of the stockholders. A separate form of proxy and a separate notice of the Meeting are being included for each account at the shared address. Registered stockholders who share an address and would like to receive a separate copy of our Annual Report and/or a separate copy of this proxy statement, or have questions regarding the householding process, may contact the Company's transfer agent: Transhare Corporation, by calling (303) 662-1112, or by forwarding a written request addressed to Transhare Corporation, Bayside Center 1, 17755 North US Highway 19, Suite # 140, Clearwater, FL 33764.

Promptly upon request, a separate copy of our Annual Report on Form 10-K and/or a separate copy of this proxy statement will be sent. By contacting Transhare Corporation, registered stockholders sharing an address can also (i) notify the Company that the registered stockholders wish to receive separate annual reports to stockholders, proxy statements, and/or Notices of Internet Availability of Proxy Materials, as applicable, in the future or (ii) request delivery of a single copy of annual reports to stockholders and proxy statements in the future if registered stockholders at the shared address are receiving multiple copies.

Many brokers, brokerage firms, broker/dealers, banks, and other holders of record have also instituted “householding” (delivery of one copy of materials to multiple stockholders who share an address). If your family has one or more “street name” accounts under which you beneficially own shares of our common stock, you may have received householding information from your broker, brokerage firm, broker/dealer, bank, or other nominee in the past. Please contact the holder of record directly if you have questions, require additional copies of this proxy statement or our Annual Report or wish to revoke your decision to household and thereby receive multiple copies. You should also contact the holder of record if you wish to institute householding.

**Where You Can Find Additional Information**

Accompanying this proxy statement is a copy of the Annual Report. Such Annual Report constitutes the Company’s annual report to its stockholders for purposes of Rule 14a-3 under the Exchange Act. Such Annual Report includes the Company’s audited financial statements for the fiscal year ended June 30, 2020 and certain other financial information, which is incorporated by reference herein. The Company is subject to the informational requirements of the Exchange Act and in accordance therewith files reports, proxy statements, and other information with the SEC. Such reports, proxy statements, and other information are available on the SEC’s website at [www.sec.gov](http://www.sec.gov). Stockholders who have questions in regard to any aspect of the matters discussed in this proxy statement should contact Yuying Zhang, our Chairman of the Board, at Room 1001, Building T5, DaZu Square, Daxing District, Beijing 100176, People’s Republic of China or by telephone on (+86) 10-58693193.